title: Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer.
abstract: We investigated the role of the lymphocyte-to-monocyte ratio (LMR) at diagnosis in patients with small cell lung cancer (SCLC) treated with standard chemotherapy. We retrospectively reviewed all SCLC patients who received frontline platinum-based chemotherapy or chemoradiotherapy. The cut-off LMR value at diagnosis was 4.19 according to time-dependent receiver-operating characteristic analysis. A total of 188 patients were divided into two groups according to the LMR at diagnosis (low vs. high LMR). Of the 171 patients evaluated for treatment response, 14 (12.4%) in the low LMR group and 1 (1.7%) in the high LMR group were non-responders (p = 0.025). In the whole patient cohort, progression-free survival and overall survival were significantly shorter in the low LMR group (low vs. high: median 6.4 vs. 7.1 months, p = 0.001; median 10.6 vs. 13.1 months, p = 0.003, respectively). On multivariate analysis, a low LMR at diagnosis was an independent unfavourable prognostic factor for predicting survival. The LMR at diagnosis could be helpful for predicting prognosis in SCLC.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Gangnam-ro 79, Jinju, 660-702, Republic of Korea.
authors.forename: Se-Il
authors.initials: SI
authors.lastname: Go
authors.forename: Rock Bum
authors.initials: RB
authors.lastname: Kim
authors.forename: Haa-Na
authors.initials: HN
authors.lastname: Song
authors.forename: Myoung Hee
authors.initials: MH
authors.lastname: Kang
authors.forename: Un Seok
authors.initials: US
authors.lastname: Lee
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Choi
authors.forename: Seung Jun
authors.initials: SJ
authors.lastname: Lee
authors.forename: Yu Ji
authors.initials: YJ
authors.lastname: Cho
authors.forename: Yi Yeong
authors.initials: YY
authors.lastname: Jeong
authors.forename: Ho Cheol
authors.initials: HC
authors.lastname: Kim
authors.forename: Jong Deog
authors.initials: JD
authors.lastname: Lee
authors.forename: Seok-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Jung-Hun
authors.initials: JH
authors.lastname: Kang
authors.forename: Hui
authors.initials: H
authors.lastname: Ling
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001772:Blood Cell Count; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality* / Q000628:therapy; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009000:Monocytes; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000097:blood / Q000401:mortality* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor